DIASORIN EXTENDS ITS CURRENT JOINT VENTURE WITH THE CHINESE GOVERNMENT TO OPEN A NEW MANUFACTURING AND RESEARCH SITE IN CHINA

Saluggia - September 23, 2020 - DiaSorin (FTSE MIB: DIA) announced today that it has reached a binding agreement aiming at the extension of its existing Joint-Venture in China with FuYuan, to Shanghai Baoshan District Government, two Chinese governmental entities, with the aim to establish its first manufacturing and research site in Shanghai.

Through the strategic partnership with FuYuan and Shanghai Baoshan District, DiaSorin will furtherly increase its positioning in the country as a high quality China based diagnostic manufacturer, thus getting access to new market opportunities exclusively available for companies manufacturing products locally.

The new plant will manufacture innovative products in the field of Oncology and Metabolic Disorders to include Hypertension.

DiaSorin has been operating in China in joint venture with the Chinese Government for more than 10 years and currently serves over 1,000 hospitals in the country as market leader for the diagnosis of prenatal infections. Once the new plant will be completed, DiaSorin will employ over 300 people in the country.

“The continuous growing importance of the Chinese market in our industry, as well as the local market’s need to increase the supply quality of diagnostic testing solutions, has led us to start this ambitious project”, commented Chen Even, Chief Commercial Officer of the DiaSorin Group. “We strongly believe that a stronger local presence will allow us to furtherly get access to tremendous new market opportunities in a country which is recognizing DiaSorin as a qualitative and innovative player”.

Research and production in the new Shanghai site will grant top-notch tests to provide innovative solutions to the increasing needs of the Chinese healthcare system. The new Group-manufacturing footprint will also allow DiaSorin to leverage on both the commercial opportunity to distribute in China several tests that are already strongly contributing to the existing business in other geographies and the research and launch of new tests specifically designed for the local market.

Finally, the reinforced presence in China will allow DiaSorin to target new market opportunities in the Class II hospitals, with an extensive tests’ menu combined with the new CLIA platform, the LIAISON XS, designed specifically for the Chinese market.

“Our presence in China has significantly increased since 2005 when we started to operate in the country. Through the last years, we transformed the Chinese commercial branch into one of the strategic business poles of our Group. We think that time has come to furtherly grow in this important market, leveraging on our extensive offer of specialty tests to strengthen our already-established position in the country”, commented Carlo Rosa, Chief Executive Officer of the DiaSorin Group. “Looking at the future of DiaSorin, it is strategic for us to reinforce our global footprint and strengthen our presence in growing and strategic markets like China, where hundreds of billions of dollars will be invested by the Government in the next ten years to further improve its healthcare system”.
DiaSorin
Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field, with 26 companies, 4 branches, 5 manufacturing facilities and 5 research and development centers.
For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.
The extensive diagnostic testing offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.
More info at www.diasoringroup.com